버리카 파마슈티컬스(VRCA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $4.45 (-4.30%), 시가총액 $0.10B, 52주 최저~최고 $0.49 ~ $9.10.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration a
버리카 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
버리카 파마슈티컬스의 현재 주가는 $4.45 (-4.30%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
버리카 파마슈티컬스의 시가총액은 약 $0.10B입니다.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The c